About
Massive Bio is a health-tech company transforming how cancer patients access clinical trials.
Operating in 17 countries across North America, Europe, and LATAM, we use proprietary AI technology to match patients to the most appropriate clinical trials—regardless of location, income, or cancer type.
We partner with pharmaceutical companies, CROs, and healthcare institutions to accelerate oncology trial enrollment, reduce dropout rates, and deliver real-world evidence.
💠 200K+ patients onboarded
💠 60+ pharma and CRO customers
💠 130+ strategic partners
💠 Founding member of CancerX & participant in the White House Cancer Moonshot
Explore how we simplify trial access and optimize recruitment across the oncology ecosystem.
🔗 Learn more: www.massivebio.com
Massive Bio was named after three converging revolutions: massive parallel sequencing, massive parallel computing, and the emerging ability to engineer biology itself. We started with symbolic AI before it was fashionable, and evolved into neurosymbolic systems that orchestrate data, computation, and biology—at scale—to bring precision oncology to patients.
Details
- Tagline:
- AI-driven system connecting cancer patients to clinical trials in real time. Industrializing the oncology action layer.
- Industry:
- Hospitals and Health Care
- Company size:
- 51-200
- Headquarters:
- Istanbul
- Org type:
- Privately Held
- Founded:
- 2014
- Specialties:
- Targeted cancer therapies, Cancer genomics, Tumor profiling technologies, Clinical trial selection, Second Opinion, Cancer Treatment, precision oncology, personalized cancer treatment options, Oncology, Cancer Care, Cancer Research, Artificial Intelligence, Machine Learning, Data Analytics, and Patient Support
- Follower count:
- 46697
- Employee count:
- 98
